Moderna Says Its COVID-19 Vaccine Was Well-Tolerated And Generated Robust Immune Response In Children Ages 6 To 11
Interim results of a Phase 2/3 trial showed Moderna's Covid-19 vaccine was well-tolerated and generated a robust immune response in children ages 6 to 11, the company said Monday.